Myelodysplastic Syndromes — Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Citation(s)
Chernov MV, Bean LJ, Lerner N, Stark GR Regulation of ubiquitination and degradation of p53 in unstressed cells through C-terminal phosphorylation. J Biol Chem. 2001 Aug 24;276(34):31819-24. Epub 2001 Jun 28.
David P Schenkein, M., Proteosome Inhibition, D. Jeffrey A. Bubis, Editor. 2003:Lebanon, New Hampshire.
Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol. 2000 Jan;108(1):93-5.
Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. Leukemia. 1995 Mar;9(3):425-32.
Felix CA Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55. Review.
Haefner B NF-kappa B: arresting a major culprit in cancer. Drug Discov Today. 2002 Jun 15;7(12):653-63. Review.
Johnson PR, Yin JA Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk Lymphoma. 1994 Dec;16(1-2):51-6. Review.
Karin M, Cao Y, Greten FR, Li ZW NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002 Apr;2(4):301-10. Review.
Parry TE The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Leuk Res. 1997 Jun;21(6):559-74. Review. Erratum in: Leuk Res 1997 Nov-Dec;21(11-12):1145.
Rosenfeld C, Kantarjian H Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. Leuk Lymphoma. 2001 May;41(5-6):493-500. Review.
Yang, H H., et al., A phase I/II study of combination treatment with bortezomib and melphalan (Vc+M) in patients with relapsed or refractory multiple myeloma (MM). Proceedings of ASCO, 2003. Abstract 2340.
A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
